Advances in the application of 1,2,4-triazole-containing hybrids as anti-tuberculosis agents

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Pai M, Behr MA, Dowdy D et al. Tuberculosis. Nat. Rev. Dis. Primers 2, e16076 (2016).
  MedlineGoogle Scholar
• 2. Saleem A, Azher M. The next pandemic – tuberculosis: the oldest disease of mankind rising one more time. Br. J. Med. Pract. 6(1), a615 (2013).
  Google Scholar
• 3. World Health Organization. Global tuberculosis report 2019. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
  Google Scholar
• 4. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N. Engl. J. Med. 372, 2127–2135 (2015).
  Medline CASGoogle Scholar
• 5. Natarajan A, Beena PM, Devnikar AV, Mali S. A systemic review on tuberculosis. Indian J. Tuberc. 67(3), 295–311 (2020).
  MedlineGoogle Scholar
• 6. Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect. Dis. 19(8), 903–912 (2019). • The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  MedlineGoogle Scholar
• 7. Garcia-Basteiro AL, Jenkins HE, Rangaka M. The burden of latent multidrug-resistant tuberculosis. Lancet Infect. Dis. 19(8), 802–803 (2019). • The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  MedlineGoogle Scholar
• 8. Umumararungu T, Mukazayire MJ, Mpenda M et al. A review of recent advances in anti-tubercular drug development. Indian J. Tuberc. 67(4), 539–559 (2020).
  MedlineGoogle Scholar
• 9. Tornheim JA, Dooley KE. The global landscape of tuberculosis therapeutics. Ann. Rev. Med. 70, 105–120 (2019).
  Medline CASGoogle Scholar
• 10. Gawad J, Bonde C. Current affairs, future perspectives of tuberculosis and antitubercular agents. Indian J. Tuberc. 65(1), 15–22 (2018).
  MedlineGoogle Scholar
• 11. Dutta A, Sarma D. Recent advances in the synthesis of quinazoline analogues as anti-TB agents. Tuberculosis 124, 101986 (2020).
  Medline CASGoogle Scholar
• 12. Xu Z, Gao C, Ren QC et al. Recent advances of pyrazole-containing derivatives as anti-tubercular agents. Eur. J. Med. Chem. 139, 429–440 (2017).
  Medline CASGoogle Scholar
• 13. Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med. Res. Rev. 40(1), 263–292 (2020). • The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  MedlineGoogle Scholar
• 14. Gatadi S, Nanduri S. New potential drug leads against MDR-MTB: a short review. Bioorg. Chem. 95, e103534 (2020). • The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  Medline CASGoogle Scholar
• 15. Huszar S, Chibale K, Singh V. The quest for the holy grail: new antitubercular chemical entities, targets and strategies. Drug Discov. Today 25(4), 772–780 (2020). • The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  Medline CASGoogle Scholar
• 16. Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. J. Infect. 78(1), 35–39 (2019).
  MedlineGoogle Scholar
• 17. Park M, Satta G, Kon OM. An update on multidrug-resistant tuberculosis. Clin. Med. 19(2), 135–139 (2019).
  MedlineGoogle Scholar
• 18. Ramirea LMN, Bargas KQ, Diaz G. Whole genome sequencing for the analysis of drug resistant strains of mycobacterium tuberculosis: a systematic review for bedaquiline and delamanid. Antibiotics 9(3), e133 (2020).
  Google Scholar
• 19. Moulin A, Bibian A, Blayo AL et al. Synthesis of 3,4,5-Trisubstituted-1,2,4-triazoles. Chem. Rev. 110(4), 1809–1827 (2010).
  Medline CASGoogle Scholar
• 20. Suresh M, Ramakanth P, Sreekanth J. 1,2,4-Triazoles: a review of synthetic approaches and the biological activity. Lett. Org. Chem. 10, 693–714 (2013).
  Google Scholar
• 21. Kuang J, Chen B, Ma S. Copper-mediated efficient three-component synthesis of 1,2,4-triazoles from amines and nitriles. Org. Chem. Front. 1, 186–189 (2014).
  Google Scholar
• 22. Amin NH, El-Saadi MT, Ibrahim AA, Abdel-Rahman HM. Design, synthesis and mechanistic study of new 1,2,4-triazole derivatives as antimicrobial agents. Bioorg. Chem. 111, e104841 (2021).
  Medline CASGoogle Scholar
• 23. Emami S, Ghobadi E, Saednia S, Hashemi SM. Current advances of triazole alcohols derived from fluconazole: design, in vitro and in silico studies. Eur. J. Med. Chem. 170, 173–194 (2019).
  Medline CASGoogle Scholar
• 24. Kun S, Begum J, Kyriakis E et al. A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: computation, synthesis, crystallography and kinetics reveal new potent inhibitors. Eur. J. Med. Chem. 147, 266–278 (2018).
  Medline CASGoogle Scholar
• 25. Gokalp M, Dede B, Tilki T, Atay CK. Triazole based azo molecules as potential antibacterial agents: synthesis, characterization, DFT, ADME and molecular docking studies. J. Mol. Struct. 1212, e128140 (2020).
  CASGoogle Scholar
• 26. Aggarwal R, Sumran G. An insight on medicinal attributes of 1,2,4-triazoles. Eur. J. Med. Chem. 205, e112652 (2020). •• The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  Medline CASGoogle Scholar
• 27. Sathyanarayana R, Poojary B. Exploring recent developments on 1,2,4-triazole: synthesis and biological applications. J. Chin. Chem. Soc. 67(4), 459–477 (2020). ••The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  CASGoogle Scholar
• 28. Kuar P, Chawla A. 1,2,4-Triazole: a review of pharmacological activities. Int. Res. J. Pharm. 8(7), 10–29 (2017).
  Google Scholar
• 29. Sharma J, Ahmad S, Shamsher A. Bioactive triazoles: a potential review. J. Chem. Pharm. Res. 4(12), 5157–5164 (2012).
  CASGoogle Scholar
• 30. Gao F, Wang T, Xiao J, Huang G. Antibacterial activity study of 1,2,4-triazole derivatives. Eur. J. Med. Chem. 173, 274–281 (2019).
  Medline CASGoogle Scholar
• 31. Zhang J, Wang S, Ba Y, Xu Z. 1,2,4-Triazole-quinoline/quinolone hybrids as potential anti-bacterial agents. Eur. J. Med. Chem. 174, 1–8 (2019).
  MedlineGoogle Scholar
• 32. Wen X, Zhou Y, Zeng J, Liu X. Recent development of 1,2,4-triazole-containing compounds as anticancer agents. Curr. Top. Med. Chem. 20(16), 1441–1460 (2020).
  Medline CASGoogle Scholar
• 33. Kaur R, Dwivedi AR, Kumar B, Kumar V. Recent developments on 1,2,4-triazole nucleus in anticancer compounds: a review. Anti-Cancer Agents Med. Chem. 16(4), 465–489 (2016).
  Medline CASGoogle Scholar
• 34. Kamboj VK, Verma PK, Dhanda A, Ranjan S. 1,2,4-Triazole derivatives as potential scaffold for anticonvulsant activity. Cent. Nerv. Syst. Agents Med. Chem. 15(1), 17–22 (2015).
  Medline CASGoogle Scholar
• 35. Ayati A, Emami S, Foroumadi A. The importance of triazole scaffold in the development of anticonvulsant agents. Eur. J. Med. Chem. 109, 380–392 (2016).
  Medline CASGoogle Scholar
• 36. Emami S, Ghobadi E, Saednia S, Hashemi SM. Current advances of triazole alcohols derived from fluconazole: design, in vitro and in silico studies. Eur. J. Med. Chem. 170, 173–194 (2019).
  Medline CASGoogle Scholar
• 37. Peyton LR, Gallagher S, Hashemzadeh M. Triazole antifungals: a review. Drugs Today 51(12), 705–718 (2015).
  Medline CASGoogle Scholar
• 38. Chu XM, Wang C, Wang WL et al. Triazole derivatives and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem. 166, 206–223 (2019).
  Medline CASGoogle Scholar
• 39. Thakkar SS, Thakor P, Doshi H, Ray A. 1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities. Bioorg. Med. Chem. 25(15), 4064–4075 (2017).
  Medline CASGoogle Scholar
• 40. Zhang S, Xu Z, Gao C et al. Triazole derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 138, 501–513 (2017).
  Medline CASGoogle Scholar
• 41. Keri RS, Patil SA, Budagumpi S, Nagaraja BM. Triazole: a promising antitubercular agent. Chem. Biol. Drug Des. 86(4), 410–423 (2015). •• The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  Medline CASGoogle Scholar
• 42. Dasan N, Babu G, George S. Molecular docking studies and synthesis of 3,4-disubstituted triazoles as Mycobacterium tuberculosis enoyl-acp reductase and CYP-51 inhibitors. Int. J. Pharm. Pharma. Sci. 11(1), 85–91 (2019).
  CASGoogle Scholar
• 43. Shcherbyna RO, Parchenko VV, Safonov AA et al. Synthesis and research of the impact of new derivatives of 4-R-3-(morpholinomethyl)-4H-1,2,4-triazole-5-thiol on cultural attributes of pathogenic M. Bovis. Res. J. Pharm. Biol. Chem. Sci. 9(2), 70–79 (2018).
  CASGoogle Scholar
• 44. Ibrar A, Shejzadi SA, Saeed F, Khan I. Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: active role of coumarin-based structural leads in drug discovery. Bioorg. Med. Chem. 26(13), 3731–3762 (2018).
  Medline CASGoogle Scholar
• 45. Shaveta S, Mishra S, Singh P. Hybrid molecules: the privileged scaffolds for various pharmaceuticals. Eur. J. Med. Chem. 124, 500–536 (2016).
  Medline CASGoogle Scholar
• 46. Kuar P, Kuar R, Goswami M. A review on methods of synthesis of 1,2,4-triazole derivatives. Int. Res. J. Pharm. 9(1), 1–35 (2018).
  Google Scholar
• 47. Raval K, Patel K, Patel S, Patel R, Patel S. A review on 1,2,4-triazoles. J. Pharm. Res. 1(1), 1–4 (2012).
  Google Scholar
• 48. Namratha P, Gaonkar SL. 1,2,4-Triazoles: synthetic strategies and pharmacological. Int. J. Pharm. Pharmaceut. Sci. 6(8), 73–80 (2014).
  CASGoogle Scholar
• 49. Al-Masoudi JA, Al-Soud YA, Al-Salihi NJ, Al-Masoudi NA. 1,2,4-Triazoles: synthetic approaches and pharmacological importance. (Review). Chem. Heterocycl. Compd. 42(11), 1377–1403 (2006).
  CASGoogle Scholar
• 50. Dhall E, Sain S, Jain S, Dwivedi J. Synthesis of triazole derivatives manifesting antimicrobial and anti-tubercular activities. Mini-Rev. Org. Chem. 15, 291–314 (2018).
  CASGoogle Scholar
• 51. Gao Y, Na LX, Xu Z et al. Design, synthesis and antibacterial evaluation of 1-[(1R,2S)-2-fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)-thione hybrids. Chem. Biodiver. 15(10), E1800261 (2018).
  MedlineGoogle Scholar
• 52. Riyadh SM, Gomha SM. Two decades of the synthesis of mono- and bis-aminomercapto[1,2,4]triazoles. RSC Adv. 10(42), 24994–25012 (2020).
  CASGoogle Scholar
• 53. Das R, Asthana GS, Suri KA, Mehta D, Asthana A. Recent developments in azole compounds as antitubercular agent. Mini-Rev. Org. Chem. 16(3), 290–306 (2019).
  CASGoogle Scholar
• 54. Bozorov K, Zhao J, Aisa HA. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: a recent overview. Bioorg. Med. Chem. 27(16), 142–163 (2019). •• The recent development of 1,2,4-triazoles with anti-TB potential was outlined to faciliate further rational design.
  Google Scholar
• 55. Zhang HZ, Gan LL, Wang H, Zhou CH. New progress in azole compounds as antimicrobial agents. Mini-Rev. Med. Chem. 17(2), 122–166 (2017).
  Medline CASGoogle Scholar
• 56. Li Z, Liu Y, Bai X et al. SAR studies on 1,2,4-Triazolo[3,4-b][1,3,4]thiadiazoles as inhibitors of Mtb shikimate dehydrogenase for the development of novel antitubercular agents. RSC Adv. 5, 97089–97101 (2015).
  CASGoogle Scholar
• 57. Deng Q, Meng J, Liu Y, Guan Y, Xiao C. IMB-SD62, a triazolothiadiazoles derivative with promising action against tuberculosis. Tuberculosis 112, 37–44 (2018).
  Medline CASGoogle Scholar
• 58. Seelam N, Shrivastava SP, Prasanthi S, Gupta S. Synthesis and in vitro study of some fused 1,2,4-triazole derivatives as antimycobacterial agents. J. Saudi Chem. Soc. 20, 411–418 (2016).
  CASGoogle Scholar
• 59. Udupi RH, Manjunath CJ. Synthesis and biological evaluation of certain N-bridged 1,2,4-triazole analogues. J. Pharm. Sci. Res. 10(2), 420–424 (2018).
  CASGoogle Scholar
• 60. Udupi RH, Manjunath CJ. Synthesis and biological evaluation of certain N-bridged 1,2,4-triazole analogues. J. Pharm. Sci. Res. 11(1), 44–49 (2019).
  CASGoogle Scholar
• 61. Kumar GVS, Prasad YR, Mallikarjuna BP, Chandrashekar SM. Synthesis and pharmacological evaluation of clubbed isopropylthiazole derived triazolothiadiazoles, triazolothiadiazines and mannich bases as potential antimicrobial and antitubercular agents. Eur. J. Med. Chem. 45, 5120–5129 (2010).
  MedlineGoogle Scholar
• 62. Kumar GVS, Rajendraprasad Y, Mallikarjuna BP, Chandrashekar SM, Kistayya C. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. Eur. J. Med. Chem. 45, 2063–2074 (2010).
  MedlineGoogle Scholar
• 63. Kumar GVS, Prasad YR, Chandrashekar SM. Synthesis and pharmacological evaluation of some novel 4-isopropyl thiazole-based sulfonyl derivatives as potent antimicrobial and antitubercular agents. Med. Chem. Res. 22, 4239–4252 (2013).
  Google Scholar
• 64. Kumar GVS, Prasad YR, Chandrashekar SM. Synthesis and pharmacological evaluation of novel 4-isopropylthiazole-4-phenyl-1,2,4-triazole derivatives as potential antimicrobial and antitubercular agents. Med. Chem. Res. 22, 938–948 (2013).
  Google Scholar
• 65. Papadopoulou MV, Bloomer WD, Rosenzweig HS. The antitubercular activity of various nitro(triazole/imidazole)-based compounds. Bioorg. Med. Chem. 25, 6039–6048 (2017).
  Medline CASGoogle Scholar
• 66. Patel NB, Khan IH, Rajani SD. Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles. Eur. J. Med. Chem. 45, 4293–4299 (2010).
  Medline CASGoogle Scholar
• 67. Patel NB, Khan IH, Rajani SD. Antimycobacterial and antimicrobial study of new 1,2,4-triazoles with benzothiazoles. Arch. Pharm. Chem. Life Sci. 10, 692–699 (2010).
  Google Scholar
• 68. Guzeldemirci NU, Kucukbasmaci O. Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety. Eur. J. Med. Chem. 45, 63–68 (2010).
  Medline CASGoogle Scholar
• 69. Eroglu B, Ozadali-Sari K, Unsal-Tan O, Sriram D, Yogeeswari P, Balkan A. Novel thiazolidinone-azole hybrids: design, synthesis and antimycobacterial activity studies. Iran J. Pharm. Res. 15(4), 783–790 (2016).
  Medline CASGoogle Scholar
• 70. Taban IM, Elshihawy AE, Torun B et al. Novel aryl substituted pyrazoles as small molecule inhibitors of cytochrome P450 CYP121A1: synthesis and antimycobacterial evaluation. J. Med. Chem. 60, 10257–10267 (2017).
  Medline CASGoogle Scholar
• 71. Kishk SM, MeLean KJ, Sood S et al. Design and synthesis of imidazole and triazole pyrazoles as Mycobacterium tuberculosis CYP121A1 inhibitors. ChemistryOpen 8, 995–1011 (2019).
  Medline CASGoogle Scholar
• 72. Nandha B, Nargund LVG, Nargund SL. Design and synthesis of some new imidazole and 1,2,4-triazole substituted fluorobenzimidazoles for antitubercular and antifungal activity. Der Pharm. Chem. 5, 317–327 (2013).
  Google Scholar
• 73. Suresh A, Suresh N, Misra S, Kumar MMK, Sekhar KVGC. Design, synthesis and biological evaluation of new substituted sulfonamide tetrazole derivatives as antitubercular agents. ChemistrySelect 1, 1705–1710 (2016).
  CASGoogle Scholar
• 74. Khanage S, Mohite P, Pandhare R, Raju A. Synthesis and pharmacological evaluation of isoxazole derivatives containing 1,2,4-triazole moiety. Marmara Pharm. J. 16, 134–140 (2012).
  CASGoogle Scholar
• 75. Dixit PP, Dixit PP, Thore SN. Hybrid triazoles: design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis. Eur. J. Med. Chem. 107, 38–47 (2016).
  Medline CASGoogle Scholar
• 76. Alshibl HM, Al-Abdullah ES, Alkahtani HM. Coumarin: a promising scaffold for design and development of bioactive agents. Curr. Bioact. Compd. 16(6), 837–852 (2020).
  CASGoogle Scholar
• 77. Hu YQ, Xu Z, Zhang S et al. Recent developments of coumarin-containing derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 136, 122–130 (2017).
  Medline CASGoogle Scholar
• 78. Feng D, Zhang A, Yang Y, Yang P. Coumarin-containing hybrids and their antibacterial activities. Arch. Pharm. 353(6), e1900380 (2020).
  Medline CASGoogle Scholar
• 79. Sudha BN, Sastry VG. Synthesis, antibacterial and antimycobacterial activity of some novel 3-(6-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-2H-chromen-2-one. Int. J. Pharm. Sci. Res. 7(5), 1302–1307 (2016).
  CASGoogle Scholar
• 80. Somagond SM, Kamble RR, Bayannavar PK et al. Click chemistry based regioselective one-pot synthesis of coumarin-3-yl-methyl-1,2,3-triazolyl-1,2,4-triazol-3(4H)-ones as newer potent antitubercular agents. Arch. Pharm. 352, e1900013 (2019).
  Medline CASGoogle Scholar
• 81. Chaudhari KS, Patel HM, Surana SJ. Pyridines: multidrug-resistant tuberculosis (MDR-TB) inhibitors. Indian J. Tuberc. 64(2), 119–128 (2017).
  MedlineGoogle Scholar
• 82. Villamizar-Mogotocoro AF, Vargas-Méndez LY, Kouznetsov VV. Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis. Eur. J. Pharm. Sci. 151, e105374 (2020).
  Medline CASGoogle Scholar
• 83. Vora D, Upahdhyay N, Tilekar K, Jain V, Ramaa CS. Development of 1,2,4-triazole-5-thione derivatives as potential inhibitors of enoyl acyl carrier protein reductase (InhA) in tuberculosis. Iran. J. Pharm. Res. 18, 1742–1758 (2019).
  Medline CASGoogle Scholar
• 84. Rajoriya V, Kashaw V, Kashaw SK. Design, synthesis, characterization and antitubercular screening of some new 1,2,4-triazoles derived from isonicotinic acid hydrazides. Lett. Drug Des. Discov. 15, 451–462 (2018).
  CASGoogle Scholar
• 85. Patel VM, Patel NB, Chan-Bacab MJ, Rivera G. Synthesis, biological evaluation and molecular dynamics studies of 1,2,4-triazole clubbed Mannich bases. Comput. Biol. Chem. 76, 264–274 (2018).
  Medline CASGoogle Scholar
• 86. Bogdanowicz A, Foks H, Gobis K, Augustynowicz-Kopec E. Synthesis and tuberculostatic activity of novel N‘-methyl-4-(pyrrolidin-1-yl)picolinohydrazide and N'-methylpyrimidine-2-carbohydrazide derivatives. Heteroatom Chem. 23, 223–230 (2012).
  CASGoogle Scholar
• 87. Bobis K, Foks H, Augustynowicz-Kopec E, Napiorkowska A. Synthesis and tuberculostatic activity of novel diverse heterocyclic compounds derived from heterocyclic carbohydrazides and methyl 2-heteroaroylhydraziecarbodithioates. Heterocycles 85(4), 871–885 (2012).
  Google Scholar
• 88. Vijayaraghavan S, Shirodkar PY. Synthesis of some 1,2,4-triazoles as potent anti-tubercular agents. Indian J. Chem. 54B, 1149–1543 (2015).
  CASGoogle Scholar
• 89. Somani RR, Shinde GK, Shirodkar PY, Sanap GJ. Synthesis of some 1,2,4-triazoles as potent anti-tubercular agents. Indian Drugs 51(1), 41–47 (2014).
  Google Scholar
• 90. Rode ND, Sonawane AD, Nawale L et al. Synthesis, biological evaluation and molecular docking studies of novel 3-aryl-5-(alkyl-thio)-1H-1,2,4-triazoles derivatives targeting Mycobacterium tuberculosis. Chem. Biol. Drug. Des. 90, 1206–1214 (2017).
  Medline CASGoogle Scholar
• 91. Thomas B, Harindran J. Design, synthesis and evaluation of antitubercular activity of amino azetidinones from isoniazid. Int. J. Pharm. Sci. Res. 7, 2795–2804 (2016).
  CASGoogle Scholar
• 92. Himaja M, Prathap KJ, Mali SV. Facile synthesis of 3,6-disubstituted-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles via oxidative cyclization of n-heteroaryl-substituted hydrazones and their biological activity. J. Heterocycl. Chem. 49, 823–827 (2012).
  CASGoogle Scholar
• 93. Oh T, Hayat F, Yoo E et al. Antitubercular activities of the novel synthesized 1,2,4-triazole derivatives. Bull. Korean Chem. Soc. 36, 43–51 (2015).
  CASGoogle Scholar
• 94. Liu B, Li F, Zhou T, Tang XQ, Hu GW. Quinoline derivatives with potential activity against multidrug-resistant tuberculosis. J. Heterocyclic Chem. 55(8), 1863–1873 (2018).
  CASGoogle Scholar
• 95. Fan YL, Wu JB, Cheng XW, Zhang FZ, Feng LS. Fluoroquinolone derivatives and their anti-tubercular activities. Eur. J. Med. Chem. 146, 554–563 (2018).
  Medline CASGoogle Scholar
• 96. Li Y, Sun F, Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. Drug Dev. Res. 80(1), 98–105 (2019).
  Medline CASGoogle Scholar
• 97. Somagond SM, Kamble RR, Kattimani PP et al. Design, docking, and synthesis of quinoline-2H-1,2,4-triazol-3(4H)-ones as potent anticancer and antitubercular agents. ChemistrySelect 3, 2004–2016 (2018).
  CASGoogle Scholar
• 98. Papadopoulou MV, Bloomer WD, Rosenzweig HS, Kaiser M. The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines. Eur. J. Med. Chem. 138, 1106–1113 (2017).
  Medline CASGoogle Scholar
• 99. Saundane AR, Kalpana R. Synthesis and biological evaluation of novel indolo[2,3-c]isoquinoline derivatives. Med. Chem. Res. 24, 1681–1695 (2015).
  CASGoogle Scholar
• 100. Xu Z, Zhang S, Feng LS et al. Synthesis and in vitro antimycobacterial and antibacterial activity of 8-OMe ciprofloxacin-hydrozone/azole hybrids. Molecules 22, e1171 (2017).
  MedlineGoogle Scholar
• 101. Peraman R, Varma RV, Reddy YP. Re-engineering nalidixic acid's chemical scaffold: a step towards the development of novel anti-tubercular and anti-bacterial leads for resistant pathogens. Bioorg. Med. Chem. Lett. 25, 4314–4319 (2015).
  Medline CASGoogle Scholar
• 102. Li Z, Bai X, Deng Q et al. Preliminary SAR and biological evaluation of antitubercular triazolothiadiazine derivatives against drug-susceptible and drug-resistant Mtb strains. Bioorg. Med. Chem. 25, 213–220 (2017).
  Medline CASGoogle Scholar
• 103. Kumar TNVG, Shenoy GG, Kar SS, Shenoy V, Bairy I. Design, synthesis and evaluation of antitubercular activity of novel 1,2,4-triazoles against MDR strain of Mycobacterium tuberculosis. Pharm. Chem. J. 51, 907–917 (2018).
  Google Scholar
• 104. Mundhe D, Chandewar AV, Shiradkar MR. Design and synthesis of substituted clubbed triazolyl thiazole as XDR & MDR antituberculosis agents Part-II. Der Pharm. Chem. 3(6), 89–102 (2011).
  CASGoogle Scholar
• 105. Patil PB, Awati SS, Kumbhoje SR, Ghotane RB, Patil SS. Synthesis and antitubercular activity of some novel N-methyl triazolone derivatives. Der Pharm. Chem. 6(1), 131–136 (2014).
  Google Scholar
• 106. Asif M, Singh A, Khan SA, Husain A. Studies on new substituted pyridazinones: synthesis and biological evaluation. Braz. J. Pharm. Sci. 54(3), e00040 (2018).
  Google Scholar
• 107. Prasad P, Kalola AG, Patel MP. Microwave assisted one-pot synthetic route to imidazo[1,2-a]pyrimidine derivatives of imidazo/triazole clubbed pyrazole and their pharmacological screening. New J. Chem. 42, 12666–12676 (2018).
  CASGoogle Scholar
• 108. Sari KO, Tan OU, Sriram D, Balkan A. Some new hydrazone derivatives bearing the 1,2,4-triazole moiety as potential antimycobacterial agents. Turkish J. Pharm. Sci. 16, 432–436 (2019).
  Medline CASGoogle Scholar
• 109. Zampieri D, Cateni F, Moneghini M et al. Imidazole and 1,2,4-triazole-based derivatives gifted with antitubercular activity: cytotoxicity and computational assessment. Curr. Top. Med. Chem. 19, 620–632 (2019).
  Medline CASGoogle Scholar
• 110. Joshi SD, More Y, Vagdevi HM, Vaidya VP, Gadaginamath GS, Kulkarni VH. Synthesis of new 4-(2,5-dimethylpyrrol-1-yl)/4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole and pyrrole ring systems: a novel class of potential antibacterial, antifungal and antitubercular agents. Med. Chem. Res. 22, 1073–1089 (2013).
  CASGoogle Scholar
• 111. Krishna KM, Inturi B, Pujar GV, Purohit MN, Vijaykumar GS. Design, synthesis and 3D-QSAR studies of new diphenylamine containing 1,2,4-triazoles as potential antitubercular agents. Eur. J. Med. Chem. 84, 516–529 (2014).
  MedlineGoogle Scholar
• 112. Tatar E, Kucukguzel SG, Karakus S et al. Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents. Marmara Pharm. J. 19, 88–102 (2015).
  CASGoogle Scholar
• 113. Sonawane AD, Rode ND, Nawale L et al. Synthesis and biological evaluation of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione as antimycobacterial agents. Chem. Biol. Drug Des. 90(2), 200–209 (2017).
  Medline CASGoogle Scholar
• 114. Patel DM, Vala RM, Sharma MG, Rajani DP, Patel HM. A practical green visit to the functionalized [1,2,4]triazolo[5,1-b]quinazolin-8(4H)one scaffolds using the group-assisted purification (GAP) chemistry and their pharmacological testing. ChemistrySelect 4, 1031–1041 (2019).
  CASGoogle Scholar